Phase I trials initiated for Cara’s Kappa Opiod agonist CR-845 « GPCR News

Tags

5-HT1A 5-HT2 5-HT2A 5-HT3 5-HT4 5-ht6 5HT1A 5HT1D 5HT2 5HT2A 5HT3 5HT4 5ht6 agonist Angiotensin II AT1 antagonist Astrazeneca Beta 2 adrenoceptor Cannabinoid CB1 Daiichi-Sankyo Dopamine Dopamine D2 Fentanyl ghrelin GlaxoSmithkline GLP-1 gpcr GSK Histamine H1 Licensing Lilly Merck Muscarinic Opioid Opioid mu phase I phase II phase III Preclinical regulatory Research Sanofi-Aventis TRPV1 Vanilloid
April 2008

M T W T F S S

May »

1 2 3 4 5 6

7 8 9 10 11 12 13

14 15 16 17 18 19 20

21 22 23 24 25 26 27

28 29 30

Phase I trials initiated for Cara’s Kappa Opiod agonist CR-845

Posted on April 29, 2008 by crimsoncanary

Cara Therapeutics have initiated a Phase 1 clinical trial of its long-acting peripheral kappa opioid receptor agonist, CR845.

Filed under: gpcr | Tagged: cara, CR-845, CR845, gpcr, kappa opioid

« Biovitrum completes study of BVT.28949 in Glaucoma Sepracor settles patent dispute with Breath Ltd over Xopenex »

Leave a Reply